US 12,005,086 B2
Microbiome related immunotherapies
Joseph Lobacki, Somerville, MA (US); Ulrich Thienel, Somerville, MA (US); Zain Kassam, Somerville, MA (US); and Marina Santiago, Somerville, MA (US)
Assigned to Finch Therapeutics Holdings LLC, Boston, MA (US)
Appl. No. 16/970,532
Filed by Finch Therapeutics Holdings LLC, Somerville, MA (US)
PCT Filed Feb. 22, 2019, PCT No. PCT/US2019/019260
§ 371(c)(1), (2) Date Aug. 17, 2020,
PCT Pub. No. WO2019/165285, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/743,792, filed on Oct. 10, 2018.
Claims priority of provisional application 62/743,794, filed on Oct. 10, 2018.
Claims priority of provisional application 62/634,503, filed on Feb. 23, 2018.
Prior Publication US 2020/0405778 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/741 (2015.01); A61K 35/37 (2015.01); A61P 35/00 (2006.01)
CPC A61K 35/741 (2013.01) [A61K 35/37 (2013.01); A61P 35/00 (2018.01)] 20 Claims
 
1. A method for increasing efficacy of an anti-cancer therapy administered to a subject having a cancer, the method comprising orally administering to the subject a therapeutic composition comprising a microbial preparation, wherein the microbial preparation comprises a non-selected community of fecal bacteria harvested from a stool of a healthy human donor, and wherein the non-selected community of fecal bacteria is lyophilized.